Article
Applied nanomedicine - Nanomagnetic detection and characterization of circulating tumor cells in HNSCC
Search Medline for
Authors
-
Dorothee Goesswein
- ENT Department, Molecular and Cellular Oncology/Nanomedicine, University Medical, Mainz
-
Dana Westmeier
- ENT Department, Molecular and Cellular Oncology/Nanomedicine, University Medical, Mainz
-
Julian Künzel
- ENT Department, Molecular and Cellular Oncology/Nanomedicine, University Medical, Mainz
-
Dominic Docter
- ENT Department, Molecular and Cellular Oncology/Nanomedicine, University Medical, Mainz
-
Roland Stauber
- ENT Department, Molecular and Cellular Oncology/Nanomedicine, University Medical, Mainz
| Published: | March 30, 2016 |
|---|
Outline
Text
Introduction: Recent advancements in nanotechnology now also set the stage for improvements in the clinics [1]. CTCs are considered to be of high clinical relevance to diagnose disease and monitor treatment. The molecular profiling of CTCs may allow to uncover novel cancer pathways [2]. However, current CTC detection methods are labor and cost intensive, precluding the analysis of CTCs in large patient cohorts.
Methods and Results: To overcome these limitations, we are developing miniaturized immuno-nanoparticle-based magnetic flow cytometry chips, allowing the swift and low cost detection of CTCs in blood [3]. We show that magnetic biosensing offers key advantages, a direct electronic read-out, and the option to apply the magnetic cell enrichment directly for cell detection. We will present proof of concept data demonstrating the feasibility of magnetic flow cytometry. However, we found that performance of the technology is dependent of the quality of the used antibody-armed ‘intelligent‘ nanoparticles and plasma proteins adsorbing to nanoprobes [4], [5].
Conclusions: Collectively, we report that nanoparticle-based magnetic flow cytometry is highly promising for the further development into an easy to use ‘point of care’ diagnostics, allowing the routine detection of CTCs in HNSCC patients’ blood samples. Applying this technology, prospective (multicenter) clinical studies are needed to clarify the value of CTCs as a surrogate clinical marker for HNSCC.
Der Erstautor gibt keinen Interessenkonflikt an.
References
- 1.
- Docter D, Westmeier D, Markiewicz M, Stolte S, Knauer SK, Stauber RH. The nanoparticle biomolecule corona: lessons learned - challenge accepted? Chem Soc Rev. 2015 Oct;44(17):6094-121. DOI: 10.1039/c5cs00217f
- 2.
- Knauer SK, Unruhe B, Karczewski S, Hecht R, Fetz V, Bier C, Friedl S, Wollenberg B, Pries R, Habtemichael N, Heinrich UR, Stauber RH. Functional characterization of novel mutations affecting survivin (BIRC5)-mediated therapy resistance in head and neck cancer patients. Hum Mutat. 2013 Feb;34(2):395-404. DOI: 10.1002/humu.22249
- 3.
- Helou M, Reisbeck M, Tedde SF, Richter L, Bär L, Bosch JJ, Stauber RH, Quandt E, Hayden O. Time-of-flight magnetic flow cytometry in whole blood with integrated sample preparation. Lab Chip. 2013 Mar;13(6):1035-8. DOI: 10.1039/c3lc41310a
- 4.
- Tenzer S, Docter D, Kuharev J, Musyanovych A, Fetz V, Hecht R, Schlenk F, Fischer D, Kiouptsi K, Reinhardt C, Landfester K, Schild H, Maskos M, Knauer SK, Stauber RH. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat Nanotechnol. 2013 Oct;8(10):772-81. DOI: 10.1038/nnano.2013.181
- 5.
- Docter D, Distler U, Storck W, Kuharev J, Wünsch D, Hahlbrock A, Knauer SK, Tenzer S, Stauber RH. Quantitative profiling of the protein coronas that form around nanoparticles. Nat Protoc. 2014 Sep;9(9):2030-44. DOI: 10.1038/nprot.2014.139
